MENU

ZYME Stock Zymeworks (ZYME, $11.22) Stochastic Oscillator left the oversold zone on May 27, 2025

A.I.dvisor
at Tickeron.com
Loading...
ZYME - Zymeworks
Stochastic signal
Bullish Trend
Odds of UP Trend
Tickeron
Stochastic signal
Price: $11.22
Daily change: -$0.32 (-2.77%)
Daily volume: 355.4K
Capitalization: $781.8M
Industry: Biotechnology
This is a signal that ZYME's price trend could be reversing, and it may be an opportunity to buy the stock or explore call options. A.I.dvisor identified 64 similar cases where ZYME's stochastic oscillator exited the oversold zone, and of them led to successful outcomes. Odds of Success:

Aroon Indicator for ZYME shows an upward move is likely

ZYME's Aroon Indicator triggered a bullish signal on May 13, 2025. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 202 similar instances where the Aroon Indicator showed a similar pattern. In of the 202 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ZYME advanced for three days, in of 295 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on May 27, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on ZYME as a result. In of 87 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for ZYME turned negative on May 22, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at .

ZYME moved below its 50-day moving average on May 22, 2025 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for ZYME crossed bearishly below the 50-day moving average on May 15, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ZYME declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.601) is normal, around the industry mean (16.080). P/E Ratio (0.000) is within average values for comparable stocks, (59.383). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.197). Dividend Yield (0.000) settles around the average of (0.039) among similar stocks. P/S Ratio (9.823) is also within normal values, averaging (268.270).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ZYME’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ZYME’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
ZYME
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a company for cancer & autoimmune treatment

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Pharmaceuticals Major
Address
108 Patriot Drive
Phone
+1 302 274-8744
Employees
277
Web
https://www.zymeworks.com